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rotein kinase C 
 
 
 
 (PKC
 
 
 
) has been implicated in Ras
 
signaling, however, a role for PKC
 
 
 
 in oncogenic
Ras-mediated transformation has not been established.
Here, we show that PKC
 
 
 
 is a critical downstream effector
of oncogenic Ras in the colonic epithelium. Transgenic
mice expressing constitutively active PKC
 
 
 
 in the colon are
highly susceptible to carcinogen-induced colon carcino-
genesis, whereas mice expressing kinase-deﬁcient PKC
 
 
 
(kdPKC
 
 
 
) are resistant to both carcinogen- and oncogenic
Ras-mediated carcinogenesis. Expression of kdPKC
 
 
 
 in
P
 
Ras-transformed rat intestinal epithelial cells blocks oncogenic
Ras-mediated activation of Rac1, cellular invasion, and
anchorage-independent growth. Constitutively active Rac1
(RacV12) restores invasiveness and anchorage-independent
growth in Ras-transformed rat intestinal epithelial cells
 
expressing kdPKC
 
 
 
. Our data demonstrate that PKC
 
 
 
 is
required for oncogenic Ras- and carcinogen-mediated
colon carcinogenesis in vivo and deﬁne a procarcinogenic
signaling axis consisting of Ras, PKC
 
 
 
, and Rac1.
 
Introduction
 
PKC
 
 
 
 plays a requisite role in Bcr–Abl-mediated resistance
to chemotherapy-induced apoptosis (Murray and Fields,
1997; Jamieson et al., 1999), and is critical for epithelial cell
polarity (Suzuki et al., 2002) and cell survival (Murray and
 
Fields, 1997; Jamieson et al., 1999). (PKC
 
 
 
 refers to the
human gene. The corresponding gene in rodents, which is
95% homologous to PKC
 
 
 
 at the amino acid level, is termed
 
PKC
 
 
 
. For clarity, we will refer to both the human and
rodent genes and gene products as PKC
 
 
 
.) Although PKC
 
 
 
has also been implicated in Ras-mediated signaling (Uberall
et al., 1999; Coghlan et al., 2000; Kampfer et al., 2001),
nothing is known about its role in oncogenic Ras-mediated
 
transformation. Activating Ras mutations occur in 
 
 
 
30% of
all human cancers (Adjei, 2001), and in 
 
 
 
50% of human
 
colon adenomas and carcinomas (Bos, 1989). Here, we
investigate the role of PKC
 
 
 
 in Ras-mediated oncogenic
transformation. Our data demonstrate that Ras-mediated
 
transformation, invasion, and anchorage-independent growth
of intestinal epithelial cells requires PKC
 
 
 
 activity. Further-
more, we demonstrate that PKC
 
 
 
 is critical for Ras- and
carcinogen-mediated colon carcinogenesis in vivo.
 
Results and discussion
 
As a first step in examining the role of PKC
 
 
 
 in colon carcino-
genesis, we assessed the expression of PKC
 
 
 
 in normal mouse
colonic epithelium and azoxymethane (AOM)-induced colon
tumors. Immunoblot analysis demonstrated that PKC
 
 
 
 is
elevated in colon tumors compared with matched, uninvolved
epithelium (Fig. 1 a). RT-PCR analysis demonstrated a
corresponding increase in PKC
 
 
 
 mRNA in colon tumors
(Fig. 1 b). PKC
 
 
 
 was also elevated in human colon carcinoma
specimens when compared with matched uninvolved colonic
epithelium (Fig. 1 c), demonstrating that elevated PKC
 
 
 
 is a
common feature of both mouse and human colon tumors.
Immunohistochemical staining confirmed the elevated
 
expression of PKC
 
 
 
 in mouse colon tumors (Fig. 2 b) compared
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with normal colonic epithelium (Fig. 2 a). Specificity of the
immunostaining was confirmed by staining with antibody in
the presence of a fivefold molar excess of the PKC
 
 
 
 peptide
used to generate the PKC
 
 
 
 antibody (Fig. 2, c and d).
The elevated expression of PKC
 
 
 
 in colon tumors sug-
gested that PKC
 
 
 
 may play an important role in colon car-
cinogenesis. To test this hypothesis, we generated transgenic
mice that express either a constitutively active PKC
 
 
 
 (ca-
PKC
 
 
 
) or kinase-deficient PKC
 
 
 
 (kdPKC
 
 
 
) in the colonic epi-
thelium. Transgenic caPKC
 
 
 
 and kdPKC
 
 
 
 mice express ele-
vated PKC
 
 
 
 protein in the colonic epithelium (Fig. 3, a and
b, top). Transgenic caPKC
 
 
 
 mice exhibited high intrinsic
PKC
 
 
 
 activity in the colonic epithelium when compared
with nontransgenic littermates (Fig. 3 a, bottom). In con-
trast, transgenic kdPKC
 
 
 
 mice exhibited decreased colonic
PKC
 
 
 
 kinase activity when compared with nontransgenic lit-
termates (Fig. 3 b, bottom; the autoradiograph in Fig. 3 b is
a longer exposure than Fig. 3 a to reveal the decreased PKC
 
 
 
activity in transgenic kdPKC
 
 
 
 mice). Neither transgenic
caPKC
 
 
 
 nor transgenic kdPKC
 
 
 
 mice exhibited demonstra-
Figure 1. PKC  is elevated mouse and human colon tumors. 
(a) Total protein lysates and (b) total RNA extracts were prepared 
from AOM-induced mouse colon tumors and uninvolved colonic 
epithelium from the same animals as described previously (Gökmen-
Polar et al., 2001). (a) Immunoblot analysis for PKC  and actin. 
(b) RT-PCR analysis for mouse PKC  and actin mRNA. Lanes N1–N4 
indicate uninvolved mouse colonic epithelium; T1–T4 indicate 
mouse colon tumors. (c) Immunoblot analysis of lysates from colon 
tumor tissue and matched, uninvolved colonic epithelium from five 
patients with colon carcinoma. Equal amounts of protein (50  g) 
were subjected to immunoblot analysis for PKC  and actin. Lanes 
N1–N5 indicate uninvolved human colonic epithelium; lanes 
T1–T5 indicate matched human colon tumors.
Figure 2. PKC  expression is elevated in AOM-induced colon tumors. 
Immunohistochemical analysis of sections from (a and c) normal, 
uninvolved epithelium and (b and d) an AOM-induced colon tumor 
from the same animal was performed using a specific PKC  antibody 
in the (a and b) absence or (c and d) presence of competing PKC  
peptide as described in Materials and methods. Bars, 50  m.
Figure 3. Transgenic caPKC  mice are highly 
susceptible to AOM-induced colon carcinogenesis. 
(a and b) Total protein lysates from scraped colonic 
epithelium from nontransgenic (Ntg) and transgenic 
(a) caPKC  (CA) or (b) kdPKC  (KD) mice were 
analyzed for PKC  protein (a and b, top) and PKC  
activity by immunoprecipitation histone kinase 
assay (a and b, bottom). (c) Colons from AOM-
treated mice were scored for ACF. CA/CA, 
homozygous caPKC  mice; CA/ , heterozygous 
caPKC  mice; Ntg, nontransgenic mice; KD/KD, 
homozygous kdPKC . Results represent the average 
ACF/animal   SEM (n   4–9; *P   0.05 vs. Ntg; 
**P   0.02 vs. Ntg). (d) H&E-stained section of a 
tubular adenoma from a nontransgenic mouse. 
(e) H&E-stained section of a carcinoma in situ from 
a caPKC  mouse. (d and e) Bars, 100  m. 
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ble changes in proliferation or differentiation markers in the
colonic epithelium (unpublished data). Next, we treated
transgenic caPKC
 
 
 
, transgenic kdPKC
 
 
 
, and nontransgenic
mice with AOM to induce colon carcinogenesis (Murray et
al., 1999; Gökmen-Polar et al., 2001) and analyzed the mice
for preneoplastic lesions, aberrant crypt foci (ACF; Fig. 3 c).
Heterozygous transgenic caPKC
 
 
 
 mice developed twice as
many ACF, and homozygous caPKC
 
 
 
 mice developed three
times as many ACF, as nontransgenic littermates (Fig. 3 c).
In contrast, homozygous transgenic kdPKC
 
 
 
 mice devel-
oped significantly fewer ACF than nontransgenic mice.
Thus, PKC
 
 
 
 activity in the colonic epithelium correlates di-
rectly with susceptibility to AOM-induced ACF formation.
Next, we assessed the effect of transgenic caPKC
 
 
 
 expres-
sion on colon tumor formation. Transgenic caPKC
 
 
 
 mice
exhibited a threefold higher incidence of tumors than non-
transgenic mice [63.6% (7/11) vs. 20% (2/10) tumor-bear-
ing mice]. In addition, transgenic caPKC
 
  mice developed
predominantly malignant intramucosal carcinomas (6/7
tumors; Fig. 3 e), whereas nontransgenic mice developed
mainly benign tubular adenomas (2/3 tumors; Fig. 3 d).
Therefore, elevated colonic PKC  activity increases the num-
ber of preneoplastic lesions and subsequent colon tumors,
and promotes tumor progression from benign adenoma to
malignant intramucosal carcinoma. Due to the low tumor
incidence in nontransgenic mice it was impractical to assess
the effect of kdPKC  on tumor formation.
Given the relationship between PKC  and Ras signaling
(Uberall et al., 1999; Coghlan et al., 2000; Kampfer et al.,
2001), we assessed whether PKC  is important for Ras-medi-
ated transformation of the intestinal epithelium. We and
others (Sheng et al., 2000; Murray et al., 2002; Yu et al.,
2003) have used rat intestinal epithelial (RIE) cells to study
Ras-mediated transformation, and elucidate the molecular
mechanisms by which PKC II promotes carcinogenesis.
Ras-transformed RIE (RIE/Ras) cells were transfected with
FLAG-tagged–, wild-type (wt) PKC  or kdPKC . Both RIE/
Ras/wtPKC  and RIE/Ras/kdPKC  cells expressed elevated
levels of PKC  when compared with RIE or RIE/Ras cells
(Fig. 4 a, top). Immunoblot analysis using an antibody to
oncogenic V12 Ras demonstrated that RIE/Ras, RIE/Ras/
wtPKC , and RIE/Ras/kdPKC  cells express comparable lev-
els of oncogenic Ras (Fig. 4 a, second from top). Actin im-
munoblots confirmed that equal amounts of protein were
loaded for each cell line (Fig. 4 a, third from top).
We next assayed RIE, RIE/Ras, RIE/Ras/wtPKC , and
RIE/Ras/kdPKC  cells for total PKC  activity (Jamieson et
al., 1999; Fig. 4 a, fourth and fifth from top). Although
RIE and RIE/Ras cells expressed equivalent levels of en-
dogenous PKC  (Fig. 4 a, fourth from top), RIE/Ras cells
exhibited elevated PKC  activity (Fig. 4 a, fifth from top).
Thus, expression of oncogenic Ras leads to activation of
endogenous PKC  while having no demonstrable effect
on PKC  expression. RIE/Ras/wtPKC  cells expressed ele-
vated PKC  protein and activity when compared with RIE
or RIE/Ras cells, whereas RIE/Ras/kdPKC  cells exhibited
elevated PKC  protein, but no increase in PKC  activity
when compared with RIE/Ras cells (Fig. 4 a, fourth and
fifth from top). Immunoprecipitation with an anti-FLAG
antibody followed by immunoblot analysis confirmed the
expression of FLAG-wtPKC  and FLAG-kdPKC  in RIE/
Ras/wtPKC  and RIE/Ras/kdPKC  cells, respectively (Fig.
4 a, second from bottom). Assay of anti-FLAG immuno-
precipitates for PKC  activity confirmed that RIE/Ras/
wtPKC  cells express catalytically active FLAG-wtPKC ,
whereas RIE/Ras/kdPKC  cells express catalytically inac-
Figure 4. PKC  is required for oncogenic Ras-
induced Rac1 activation and invasion in vitro. 
(a) RIE cells were stably transfected with empty 
vector (RIE), Ras (RIE/Ras), Ras and wtPKC  (RIE/
Ras/wtPKC ), or Ras and dnPKC  (RIE/Ras/kdPKC ). 
Total cell lysates were subjected to immunoblot 
analysis for PKC  (top), oncogenic V12 Ras (second 
from top) and  -actin (third from top). Immunopre-
cipitates using a specific PKC  antibody were 
analyzed for PKC  expression (fourth from top) and 
PKC  activity (fifth from top). Anti-FLAG immuno-
precipitates were analyzed PKC  expression 
(second from bottom) and PKC  activity (bottom). 
(b) Anchorage-dependent growth of RIE cells and 
RIE cell transfectants. Data represent the mean   
SD from three independent determinations. 
(c) Active (GTP bound) Rac1 was isolated from the 
indicated RIE cell transfectants: control empty vector; 
Ras; Ras and RacN17; Ras and kdPKC ; and Ras 
and kdPKC  and RacV12. Immunoblot analysis was 
performed for active Rac1 (top), total cellular Rac1 
(middle), and actin (bottom). The asterisk indicates 
the migration of Myc-tagged, virally expressed 
Rac1 mutants. (d) The indicated RIE transfectants 
were assayed for invasion. Data represent the 
average number of cells invading into the bottom 
chamber   SD from three independent experiments. 
*P   0.02 versus RIE   control vector; **P   0.02 
versus RIE/Ras; ***P   0.005 versus RIE/Ras/kdPKC .800 The Journal of Cell Biology | Volume 164, Number 6, 2004
tive FLAG-kdPKC  (Fig. 4 a, bottom). These data demon-
strate that oncogenic Ras activates both endogenous and
transfected PKC , and confirm that our kdPKC  construct
is deficient in kinase activity.
RIE/Ras cells exhibited an increase in anchorage-depen-
dent growth rate and saturation density compared with RIE
cells (Fig. 4 b). Expression of wtPKC  or kdPKC  had little
effect on the Ras-mediated increase in growth rate or satura-
tion density (Fig. 4 b). RIE cells expressing wtPKC  or kd-
PKC  in the absence of oncogenic Ras exhibited no demon-
strable change in growth rate compared with RIE cells, and
no signs of cellular transformation (unpublished data).
Because Ras transformation is dependent on activation of
the small molecular weight GTPase, Rac1 (Qiu et al., 1995),
we measured Rac1 activity in RIE/Ras cells (Fig. 4 c). As ex-
pected, RIE/Ras cells exhibit elevated Rac1 activity when
compared with RIE cells (Fig. 4 c). Expression of either a
dominant negative Rac1 (RacN17) mutant (Qiu et al.,
1995) or kdPKC  blocked Ras-mediated Rac1 activation. In
contrast, expression of a constitutively active Rac1 (RacV12)
mutant (Qiu et al., 1995) had little effect on Ras-mediated
activation of endogenous Rac1. Expression of wtPKC  in
the absence of oncogenic Ras was not sufficient to induce
Rac1 activity (unpublished data). Thus, oncogenic Ras acti-
vates Rac1 in a PKC -dependent fashion.
Both Ras and Rac1 have been implicated in cellular mo-
tility and invasion (De Corte et al., 2002) and RIE/Ras
cells exhibit an invasive phenotype (Fujimoto et al., 2001).
Therefore, we assessed whether the invasive phenotype ob-
served in RIE/Ras cells is dependent on Rac1 and PKC . As
expected, RIE/Ras cells are highly invasive, whereas RIE
cells are not (Fig. 4 d). Expression of RacN17 or kdPKC  in
RIE/Ras cells blocks Ras-mediated invasion (Fig. 4 d). How-
ever, expression of RacV12 in RIE/Ras/kdPKC  cells par-
tially restores invasiveness. Thus, oncogenic Ras-mediated
cellular invasion is dependent on both Rac1 and PKC . In-
terestingly, expression of either wtPKC  or caPKC  in the
absence of oncogenic Ras failed to induce invasion, indicat-
ing that PKC  is necessary for Ras-mediated invasion, but is
not sufficient to induce invasion in the absence of oncogenic
Ras (unpublished data).
RIE/Ras cells exhibit anchorage-independent growth in
soft agar, whereas RIE cells do not (Fig. 5, a and b). Expres-
sion of wtPKC  significantly enhances, and expression of
kdPKC  blocks, soft agar growth of RIE/Ras cells (Fig. 5, a
and b). Furthermore, expression of RacV12 in RIE/Ras/kd-
PKC  cells restores soft agar growth (Fig. 5 c). Expression of
RacV12 in RIE cells in the absence of oncogenic Ras does
not induce soft agar growth, indicating that expression of ac-
tive Rac1 alone is not sufficient to cause cellular transforma-
tion (Fig. 5 c), which is consistent with previous reports that
RacV12 exhibits very weak transforming potential (Khos-
ravi-Far et al., 1995). These data demonstrate that PKC 
plays a critical role in Ras-mediated transformation of RIE
cells because PKC  is required for Ras-mediated activa-
tion of Rac1, cellular invasion, and anchorage-independent
growth. Our data place PKC  downstream of oncogenic Ras
and upstream of Rac1 in a pathway that stimulates invasive-
ness and soft agar growth, two hallmarks of the transformed
phenotype. Next, we assessed the importance of PKC  in
Ras-mediated colon carcinogenesis in vivo using transgenic
mice expressing a latent oncogenic K-ras allele (G12D) that
is activated by spontaneous recombination (Johnson et al.,
2001). Latent K-ras (K-Ras
LA2) mice develop Ras-dependent
lung carcinomas and colonic ACF (Johnson et al., 2001).
We bred our transgenic kdPKC  mice with K-Ras
LA2 mice to
generate bitransgenic K-Ras
LA2/kdPKC  mice, and assessed
them for spontaneous ACF development (Fig. 5 d). K-Ras
LA2/
kdPKC  mice developed significantly fewer ACF in the
proximal colon than K-Ras
LA2 mice. These data are consis-
tent with our results in RIE/Ras cells in vitro, and demon-
Figure 5. Expression of dnPKC  blocks Ras-mediated transformation 
of the intestinal epithelium in vitro and in vivo. (a and b) RIE cells 
were stably transfected with control empty vector (RIE), Ras (RIE/Ras), 
Ras and wtPKC  (RIE/Ras/wtPKC ), or Ras and kdPKC  (RIE/ Ras/
kdPKC ), and evaluated for growth in soft agar. (a) Representative 
experimental results. Numbers in parentheses represents number of 
colonies/dish. (b) Values represent the average of three independent 
experiments   SEM. *P   0.002 versus RIE/Ras. (c) The indicated 
RIE cell transfectants were analyzed as described in panel a. Values 
represent the average of five determinations   SEM. *P   0.008 
versus RIE/Ras; **P   0.0001 versus RIE/Ras/kdPKC . (d) 12-wk-old 
K-Ras
LA2 and K-Ras
LA2/kd PKC  mice were analyzed for ACF in the 
proximal colon. Average number of ACF per mouse is plotted   the 
SEM; n   5; *P   0.04.PKC  is required for Ras transformation | Murray et al. 801
strate that PKC  is critical for oncogenic K-ras–mediated co-
lon carcinogenesis in vivo.
Our results provide direct evidence that PKC  and Rac1
are necessary for the transformed phenotype induced by on-
cogenic Ras. Rac1 has been shown to be required for trans-
formation by both H-Ras and K-Ras, the two most com-
monly mutated forms of Ras in human cancers. Our data
demonstrate that PKC  is also required for both H-Ras–
and K-Ras–mediated transformation. Although H-Ras and
K-Ras have both common and distinct effectors, both of these
Ras isoforms activate Rac1, though K-Ras appears more ef-
fective than H-Ras (Walsh and Bar-Sagi, 2001). We have
shown that H-Ras induces Rac1 activity through a PKC -
dependent pathway and that PKC  is required for K-Ras–
mediated colon carcinogenesis. Given the increased pro-
pensity of K-Ras to activate Rac1, it is likely that the
Ras→PKC →Rac1 pathway we have elucidated in RIE cells
is also important for K-Ras–mediated colon carcinogenesis
in vivo. Interestingly, PKC  and Rac1 have also been impli-
cated in epithelial cell polarity through formation of com-
plexes containing PKC , Par6, and Rac1 (Noda et al.,
2001). Rac1 is thought to regulate PKC  activity within
these complexes to affect cell polarity (Noda et al., 2001).
Our data now implicate signaling through PKC –Par6–
Rac1 complexes in Ras-mediated transformation.
In this report, we present conclusive evidence that PKC  is
critical for colonic epithelial cell transformation both in
vitro and in vivo. Interestingly, disruption of PKC  signaling
by kdPKC  has little effect on normal intestinal epithelial
cell homeostasis in vitro and in vivo, suggesting that PKC 
may be an attractive target for development of novel thera-
peutics against colon cancer.
Materials and methods
Analysis of PKC  expression in mouse and human colon tumors
AOM-induced mouse colon tumors were produced in C57Bl/6 mice as de-
scribed previously (Gökmen-Polar et al., 2001). Fresh frozen tissue from
human colon carcinomas and uninvolved colonic epithelium was ob-
tained from surgical specimens. Isolation of RNA and protein for RT-PCR
and immunoblot analysis, respectively, was performed as described previ-
ously (Gökmen-Polar et al., 2001). Immunoblot analysis for PKC  and actin
was conducted using isozyme-specific antibody against PKC  and actin
(Santa Cruz Biotechnology, Inc.) as described previously (Murray and
Fields, 1997; Gökmen-Polar et al., 2001). We determined previously that
this PKC  antibody recognizes PKC  but not PKC  (Murray and Fields,
1997). Primers for RT-PCR analysis were as follows: PKC  forward primer,
5 -GCTTATGTTTGAGATGATGGCGG-3 , and PKC  reverse primer, 5 -GTG-
ACAACCCAATCGTTCCG-3 ; and actin forward primer, 5 -GTGGGC-
CGCTCTAGGCACCAA-3 , and actin reverse primer, 5 -CTCTTTGATGT-
CACGCACGATTTC-3 . Colon tumors and uninvolved colonic epithelium
from AOM-treated mice were fixed in 10% buffered formalin, sectioned,
and subjected to antigen retrieval (Vector Laboratories). Immunohis-
tochemical detection of PKC  was performed using the specific PKC  anti-
body (Santa Cruz Biotechnology, Inc.) and the DAKO LSAB2 (DAB) detec-
tion system (DakoCytomation). Specificity of immunostaining for PKC  was
demonstrated by inclusion of a fivefold molar excess of the peptide used to
generate the PKC  antibody (Santa Cruz Biotechnology, Inc.) in the anti-
body dilution. Digital images were acquired on a microscope (model
DX51; Olympus) equipped with a DP70 digital camera using a 20  objec-
tive lens. Images were captured using the DP Controller software and pro-
cessed in Adobe Photoshop.
Production of transgenic mice and carcinogenesis studies
Human caPKC  and kdPKC  cDNAs were generated and characterized
previously (Jamieson et al., 1999; Lu et al., 2001). Transgenic caPKC 
and kdPKC  mice were generated on a C57Bl/6 background using the
Fabpl
4x at  132 promoter (Simon et al., 1997; provided by J. Gordon, Wash-
ington University, St. Louis, MO) to direct transgene expression to the co-
lonic epithelium (Murray et al., 1999). Isolation of colonic epithelium, im-
munoblot analysis for PKC , and immunoprecipitation histone kinase
assays were described previously (Jamieson et al., 1999; Murray et al.,
1999). Transgenic caPKC , transgenic kdPKC , and nontransgenic mice were
injected with either 10 mg/kg AOM or saline as described previously (Gökmen-
Polar et al., 2001). ACF analysis was performed 12 wk after the last AOM
injection (Murray et al., 2002) using well-defined criteria (McLellan et al.,
1991). Mice were analyzed at 40 wk for tumor number, size, location, and
pathological grade as described previously (Gökmen-Polar et al., 2001).
All tumors were classified as either tubular adenomas or intramucosal car-
cinomas (carcinoma in situ) by Z. Gatalica, a board-certified pathologist.
Digital images of the tumors were captured on a microscope (model
Eclipse E600; Nikon) equipped with a ProgRes C14 camera (Jenoptik) us-
ing a 20  objective lens. Images were acquired using ProgRes C14 soft-
ware with Microsoft Photoeditor and processed with Microsoft Photoshop.
Transgenic K-ras
LA2 mice (Johnson et al., 2001; provided by T. Jacks,
Massachusetts Institute of Technology, Cambridge, MA) were bred to
transgenic kdPKC  mice to obtain bitransgenic K-ras
LA2/kdPKC  mice. At 12
wk old, transgenic K-ras
LA2 and bitransgenic K-ras
LA2/kdPKC  mice were as-
sessed for spontaneous ACF formation (McLellan et al., 1991; Murray et
al., 1999).
RIE cell transfections and cellular analyses
RIE cells and derivatives were grown in DME containing 5% FBS as de-
scribed previously (Ko et al., 1998). RIE/Ras cells were described else-
where (Sheng et al., 2000; provided by H.M. Sheng, University of Texas
Medical Branch [UTMB], Galveston, TX). Microarray analysis of RIE/Ras
cells demonstrated that these cells do not express PKC  (unpublished
data). Human wtPKC  and kdPKC  cDNAs were cloned into the pBABE/
FLAG/puro retroviral expression vector and virus stocks were produced us-
ing Phoenix-E cells (provided by G. Nolan, Stanford University, Palo Alto,
CA). Puromycin-resistant, stable transfectants were generated as described
at http://www.stanford.edu/group/nolan/retroviral_systems/retsys.html. Ex-
pression of FLAG-epitope–tagged PKC  was confirmed by immunoblot
analysis using anti-FLAG antibody (Sigma-Aldrich), and PKC  kinase activ-
ity was determined by immunoprecipitation histone kinase assay as de-
scribed previously (Jamieson et al., 1999).
Recombinant retroviruses containing Myc-tagged RacN17 or Myc-
tagged RacV12 were generated by excising the Myc-tagged Rac1 con-
structs from pEXV/Rac vectors (Qiu et al., 1995) with EcoRI and ligating
them into the EcoRI site of the LZRS-GFP retrovirus. The entire coding se-
quence of each construct was confirmed by DNA sequence analysis.
LZRS-GFP-Rac1 retroviruses were used to infect RIE cells and derivative
cell lines using a protocol described previously (Ireton et al., 2002). Rac1
activity was assessed by affinity isolation of GTP-bound Rac1 using a pro-
tocol described previously (Sander et al., 1998). Active GTP-bound Rac1
and total Rac1 were identified by immunoblot analysis using a Rac1 mAb
(BD Biosciences) and quantitated by densitometry.
Invasiveness of RIE cell transfectants was assessed in Transwell inserts
precoated with Matrigel (6.5-mm diam, 8- m pore size; BD Biosciences).
DME containing 10% FBS was added to the bottom chamber and 5   10
4
cells were suspended in 500  l of serum-free DME and placed in the top
chamber of the Transwell insert. Cells were incubated for 22 h at 37 C in
5% CO2, at which time noninvading cells were removed from the top
chamber. Cells that had invaded through the Matrigel-coated filter were
fixed in 100% methanol, stained with crystal violet, and counted on a mi-
croscope (Nikon) using a calibrated ocular grid. 15 representative areas of
the bottom chamber were counted to determine the number of invasive
cells in each well.
To assess anchorage-independent growth, RIE cell transfectants were
suspended in DME supplemented with 10% FBS, 1.5% agarose, and a 1%
insulin, transferrin, and selenium solution (Sigma-Aldrich), and plated (300
cells/60-mm dish) on a layer of 1.5% agar containing the same medium.
Cell colonies were fixed with 20% methanol and stained with Giemsa after
7–14 d in culture and quantified under a dissecting microscope (Nikon).
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